Table 1.
Drugs | Active ingredients | Administration | Average dosage/target range | Half-life |
---|---|---|---|---|
Revia®, Depade® | Naltrexone | Oral (tablet) | 50 mg, 1×/day | 13 hours45 |
Vivitrol® XR | Naltrexone | IM | 380 mg, 1×/month | 5–10 days59 |
Methadose®, Diskets®, Dolophine® | Methadone HCl | Oral (dispersible tablet in liquid), IM | 2:1 (parental-to-oral ratio), 80–120 mg oral60 | 8–59 hours61 |
Xtampza® ER | Oxycodone HCl | Oral (capsule) | 9–36 mg, 2×/day62 | 5.6 hours63 |
Narcan® | Naloxone HCl | Nasal spray | 4 mg, 1 spray33 | 0.5–1.35 hours64 |
Suboxone® | Buprenorphine/naloxone | Oral (SL) tablet, buccal (film) | 4/1 mg, 8/2 mg, 12/3 mg62 | 24–42 hours/2–12 hours65 |
Bunavail® | Buprenorphine/naloxone | Buccal (film) | 2.1/0.3 mg, 4.2/0.7 mg, 6.3/1 mg66 | 16.4–27.5 hours/1.9–2.4 hours67 |
Zubsolv® | Buprenorphine/naloxone | Oral (SL) tablet | Two 5.7 mg/1.4 mg tablets 1×/day (11.4 mg/2.8 mg)68 | 24–48 hours/2–12 hours65 |
Probuphine® | Buprenorphine HCl | Subdermal implant | Four implants deliver equivalent to daily doses <8 mg suboxone55 | 24–48 hours55 |
Abbreviations: IM, intramuscular; IV, intravenous; SL, sublingual.